Patents by Inventor Arnold Levine
Arnold Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938124Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a cancer with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with a secondary agent to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: June 15, 2021Date of Patent: March 26, 2024Assignee: PMV Pharmaceuticals, Inc.Inventors: Arnold Levine, Melissa Dumble
-
Publication number: 20230348592Abstract: Disclosed are treatments for cancer that enhance a patient immune systems' ability to detect and attack cancer. The present disclosure provides methods for treating cancer in a subject in need thereof comprising administering to the subject an effective amount of a pregnancy specific glycoprotein (PSG) inhibitor.Type: ApplicationFiled: May 10, 2021Publication date: November 2, 2023Inventors: James C. Mathews, Saad Nadeem, Maryam Pouryahya, Zehor Belkhatir, Joseph O. Deasy, Allen Robert Tannenbaum, Arnold Levine
-
Publication number: 20230049952Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: ApplicationFiled: June 15, 2021Publication date: February 16, 2023Inventors: Arnold Levine, David Mack, Binh Vu, Thomas Davis, Melissa Dumble
-
Publication number: 20230033324Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a cancer with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with a secondary agent to reduce the progression of cancers that contain a p53 mutation.Type: ApplicationFiled: June 15, 2021Publication date: February 2, 2023Inventors: Arnold Levine, Melissa Dumble
-
Publication number: 20210403945Abstract: Provided herein are compositions and methods for studying cancer therapeutics and etiology, for example, mouse cancer models, cancer cell lines, and uses thereof. Human p53 knock-in (Hupki) mice with a Y220 (e.g., Y220C, Y220H, or Y220S) mutation in p53 are provided. These Hupki-Y220 mice can be used, for example, to examine tumorigenesis in different tissues, investigate mechanisms of gain of function, develop mouse models of cancer, generate cancer cell lines that can be implanted into recipient mice, and test potential therapeutics.Type: ApplicationFiled: June 24, 2021Publication date: December 30, 2021Inventors: Arnold Levine, David Mack, Anna Puzio-Kuter, Lizhong Xu, Thomas W. Davis, Melissa Dumble
-
Publication number: 20210405056Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The methods described herein can detect and quantify the ability of a therapeutic agent to reconform a mutant conformation of mutant p53 to a conformation that possesses physiological activity of wild type p53. The disclosed method can be used as a companion diagnostic to detect and quantify the efficacy of a therapeutic agent in reducing the progression of cancers that contain a p53 mutation.Type: ApplicationFiled: June 22, 2021Publication date: December 30, 2021Inventors: Arnold LEVINE, Jonathan OLINER, Thomas W. DAVIS, Mary Kate McBRAYER
-
Patent number: 10815277Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.Type: GrantFiled: August 4, 2016Date of Patent: October 27, 2020Assignee: INSTITUTE FOR ADVANCED STUDYInventors: Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine
-
Publication number: 20200268786Abstract: The present invention relates to a composition comprising an isolated, single stranded RNA molecule having a nucleotide sequence comprising 20 or more bases and a pattern of CpG dinucleotides defined by a strength of statistical bias greater than or equal to zero, and a pharmaceutically acceptable carrier suitable for injection. The present invention also relates to a kit comprising a cancer vaccine and the composition of the present invention as an adjuvant to the cancer vaccine. The present invention further relates to a method of treating a subject for a tumor and a method of stimulating an immune response.Type: ApplicationFiled: February 10, 2020Publication date: August 27, 2020Inventors: Benjamin D. Greenbaum, Nina Bhardwaj, Arnold Levine, Remi Monasson, Simona Cocco
-
Publication number: 20180036334Abstract: The present invention relates to a composition comprising an isolated, single stranded RNA molecule having a nucleotide sequence comprising 20 or more bases and a pattern of CpG dinucleotides defined by a strength of statistical bias greater than or equal to zero, and a pharmaceutically acceptable carrier suitable for injection. The present invention also relates to a kit comprising a cancer vaccine and the composition of the present invention as an adjuvant to the cancer vaccine. The present invention further relates to a method of treating a subject for a tumor and a method of stimulating an immune response.Type: ApplicationFiled: February 16, 2016Publication date: February 8, 2018Inventors: Benjamin GREENBAUM, Nina BHARDWAJ, Arnold LEVINE, Remi MONASSON, Simona COCCO
-
Publication number: 20170073376Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.Type: ApplicationFiled: August 4, 2016Publication date: March 16, 2017Inventors: Raul RABADAN, Michael KRASNITZ, Harlan ROBINS, Daniela WITTEN, Arnold LEVINE
-
Patent number: 9422342Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.Type: GrantFiled: July 12, 2007Date of Patent: August 23, 2016Assignee: Institute of Advanced StudyInventors: Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine
-
Publication number: 20140370544Abstract: The present invention relates to methods and algorithms that can be used to identify sequence motifs that are either under- or over-represented in a given nucleotide sequence as compared to the frequency of those sequences that would be expected to occur by chance, or that are either under- or over-represented as compared to the frequency of those sequences that occur in other nucleotide sequences, and to methods of scoring sequences based on the occurrence of these sequence motifs. Such sequence motifs may be biologically significant, for example they may constitute transcription factor binding sites, mRNA stability/instability signals, epigenetic signals, and the like. The methods of the invention can also be used, inter alia, to classify sequences or organisms in terms of their phylogenetic relationships, or to identify the likely host of a pathogenic organism. The methods of the present invention can also be used to optimize expression of proteins.Type: ApplicationFiled: July 9, 2014Publication date: December 18, 2014Inventors: Harlan ROBINS, Arnold LEVINE, Michael KRASNITZ
-
Publication number: 20130345164Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.Type: ApplicationFiled: April 21, 2011Publication date: December 26, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
-
Publication number: 20100203081Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.Type: ApplicationFiled: July 12, 2007Publication date: August 12, 2010Applicant: INSTITUTE FOR ADVANCED STUDYInventors: Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine
-
Publication number: 20090208955Abstract: The present invention relates to methods and algorithms that can be used to identify sequence motifs that are either under- or over-represented in a given nucleotide sequence as compared to the frequency of those sequences that would be expected to occur by chance, or that are either under- or over-represented as compared to the frequency of those sequences that occur in other nucleotide sequences, and to methods of scoring sequences based on the occurrence of these sequence motifs. Such sequence motifs may be biologically significant, for example they may constitute transcription factor binding sites, mRNA stability/instability signals, epigenetic signals, and the like. The methods of the invention can also be used, inter alia, to classify sequences or organisms in terms of their phylogenetic relationships, or to identify the likely host of a pathogenic organism. The methods of the present invention can also be used to optimize expression of proteins.Type: ApplicationFiled: November 30, 2006Publication date: August 20, 2009Applicant: INSTITUTE FOR ADVANCE STUDYInventors: Harlan Robins, Michael Krasnitz, Arnold Levine
-
Publication number: 20070041964Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.Type: ApplicationFiled: July 17, 2006Publication date: February 22, 2007Inventors: David Botstein, Robert Cohen, Audrey Goddard, Austin Gurney, Kenneth Hillan, David Lawrence, Arnold Levine, Diane Pennica, Margaret Roy, William Wood
-
Publication number: 20040132052Abstract: DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.Type: ApplicationFiled: July 28, 2003Publication date: July 8, 2004Applicant: Genentech, Inc.Inventors: Arnold Levine J., Diane Pennica